Mainz Biomed, maker of the ColoAlert test, inked a private placement deal for $6 million and is looking to shed its c...
Mainz Biomed secured $6 million in a private placement and plans to divest ColoAlert as it pivots from colorectal cancer screening to build a pancreatic cancer detection program for the U.S. market.
Why it mattersAfter securing a $6 million private placement, Mainz Biomed will sell ColoAlert to fund U.S.